Irvin Marguerite R, Kabagambe Edmond K, Tiwari Hemant K, Parnell Laurence D, Straka Robert J, Tsai Michael, Ordovas Jose M, Arnett Donna K
Department of Epidemiology, University of Alabama at Birmingham, USA.
Circ Cardiovasc Genet. 2010 Oct;3(5):462-7. doi: 10.1161/CIRCGENETICS.110.950667. Epub 2010 Aug 21.
Although much is known about the effect of Apolipoprotein E (APOE) alleles on fasting lipid concentrations, less is known about the effect of APOE alleles on postprandial triglyceridemia or the triglyceride response to fenofibrate.
We evaluated the effects of the APOE locus on fasting and postprandial triglyceride concentrations as part of the Genetics of Lipid Lowering and Diet Network (GOLDN) study. Participants were evaluated after a high-fat meal challenge before (n=1072) and after 3 weeks of daily treatment with 160 mg of fenofibrate (n=738). Mixed models adjusted for sex, age, waist circumference, and family relationship were used to examine the association of the ε4 carrier and ε2 carrier status versus ε3 homozygotes with fasting triglycerides and the area under the curve (AUC) for triglycerides during the high-fat meal challenge. Compared with the ε3/ε3 genotype, ε2 carriers had on average higher fasting triglyceride concentrations (130.5 mg/dL versus 109.3 mg/dL, P<0.001). After fenofibrate treatment, the APOE genotype differences persisted in the fasting state (ε2 carriers: 85.1 mg/dL versus ε3/ε3: 75.9 mg/dL, P<0.05). Carriers of the ε4 allele had significantly higher fasting triglyceride concentrations only prefenofibrate (120.9 mg/dL versus 109.3 mg/dL, P=0.008). APOE alleles did not have an effect on response to fenofibrate. Postprandial triglycerides were significantly higher for ε2 carriers versus ε3 homozygotes (but not ε4 carriers) both before and after fenofibrate treatment (P=0.01 and P=0.005, respectively).
APOE polymorphisms are important determinants of triglyceride concentrations, especially in the fasting state.
尽管关于载脂蛋白E(APOE)等位基因对空腹血脂浓度的影响已有很多了解,但对于APOE等位基因对餐后甘油三酯血症或非诺贝特治疗后甘油三酯反应的影响却知之甚少。
作为降脂与饮食遗传学网络(GOLDN)研究的一部分,我们评估了APOE基因座对空腹和餐后甘油三酯浓度的影响。在高脂餐激发试验前(n = 1072)和每日服用160 mg非诺贝特治疗3周后(n = 738)对参与者进行评估。使用针对性别、年龄、腰围和家族关系进行调整的混合模型,来检验ε4携带者和ε2携带者状态与ε3纯合子相比,与空腹甘油三酯以及高脂餐激发试验期间甘油三酯曲线下面积(AUC)之间的关联。与ε3/ε3基因型相比,ε2携带者的空腹甘油三酯浓度平均更高(130.5 mg/dL对109.3 mg/dL,P<0.001)。非诺贝特治疗后,APOE基因型差异在空腹状态下仍然存在(ε2携带者:85.1 mg/dL对ε3/ε3:75.9 mg/dL,P<0.05)。仅在服用非诺贝特前,ε4等位基因携带者的空腹甘油三酯浓度显著更高(120.9 mg/dL对109.3 mg/dL,P = 0.008)。APOE等位基因对非诺贝特的反应没有影响。在非诺贝特治疗前后,ε2携带者的餐后甘油三酯均显著高于ε3纯合子(但不是ε4携带者)(分别为P = 0.01和P = 0.005)。
APOE基因多态性是甘油三酯浓度的重要决定因素,尤其是在空腹状态下。